Captor Therapeutics SA

As of June 30, 2026, Captor Therapeutics SA carries a market capitalization of 485.14M, placing it among publicly traded companies globally. Its enterprise value stands at 416.30M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Captor Therapeutics SA's next confirmed earnings release is scheduled for December 2, 2026.

As of June 30, 2026, Captor Therapeutics SA has 6.33M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 218.46, and the price-to-book ratio stands at 7.46.

These figures are as of June 30, 2026. The EV/Sales ratio of 207.53 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 416.30M versus a market cap of 485.14M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Captor Therapeutics SA maintains a current ratio of 5.41, meaning it holds 5.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 4.09, indicating elevated leverage, while an interest coverage ratio of -164.78 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Captor Therapeutics SA posted a negative return on equity (ROE) of -80.62, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -65.80, reflecting losses generated across the asset base. The company generates approximately 18,072.07 in revenue per employee across its workforce of 111.00, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, Captor Therapeutics SA recorded 27,000.00 in income tax expense. The company reported a pretax loss of -44.26M and -44.28M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, Captor Therapeutics SA's stock has gained approximately 32.19% over the past 52 weeks. The 50-day moving average sits at 68.56, while the 200-day moving average is 75.98.

Over the twelve months ended June 30, 2026, Captor Therapeutics SA generated 2.01M in revenue and converted that into -44.28M in net income, yielding earnings per share of -7.81. EBITDA reached -42.68M, while operating income came in at -46.36M.

As of June 30, 2026, Captor Therapeutics SA holds 71.50M in cash and equivalents against 2.66M in total debt, resulting in a net debt position of -2.40M. Total book value stands at 65.07M, with working capital of 60.94M providing operational flexibility.

Captor Therapeutics SA produced -74.41M in operating cash flow over the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Captor Therapeutics SA posted a gross margin of 192.12, reflecting its pricing power and cost economics. The operating margin of -2,311.12 and net profit margin of -2,207.63 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -17.13: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -19.32, meaning Captor Therapeutics SA raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of June 30, 2026, Captor Therapeutics SA has an Altman Z-Score of 14.34, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.